en · de · es · fr · pt
bench-notes.peptides6088.com › Guide › Background And Research Context — Background and Details

Background And Research Context — Background and Details

By Editorial Desk · published 2025-07-20 · last reviewed 2025-08-20 · Guide

peptide research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-08-20. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Regulation and Detection Context

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Background and Development History

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Related pages on this site

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Identity and Research Origin

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Handling And Analytical Properties

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Notes from published material

=== Eating disorders === Antidepressants are recommended as an alternative or additional first step to self-help programs in the treatment of bulimia nervosa. SSRIs (fluoxetine in particular) are preferred over other anti-depressants due to their acceptability, tolerability, and superior reduction of symptoms in short-term trials. Long-term efficacy remains poorly characterized. Similar recommendations apply to binge eating disorder. SSRIs provide short-term reductions in binge eating behavior, but have not been associated with significant weight loss. Clinical trials have generated mostly negative results for the use of SSRIs in the treatment of anorexia nervosa. Treatment guidelines from the National Institute of Health and Clinical Excellence recommend against the use of SSRIs in this disorder. Those from the American Psychiatric Association note that SSRIs confer no advantage regarding weight gain, but that they may be used for the treatment of co-existing depression, anxiety, or OCD.

=== "Hakbang ng Maisug" rallies === Additional nationwide protests, called Hakbang ng Maisug (brave) prayer rallies, were held in Dumaguete, Tagum, and Angeles by Duterte and Quiboloy's supporters, who voiced their grievances against the Marcos administration. Particularly among these grievances included their opposition to proposed constitutional amendments and to the increased US military presence in the country, as well as denouncement of perceived censorship under the administration. In one of the rallies, Duterte notably accused Marcos of plotting to extend his term beyond the current term limit of the Constitution and of being a drug addict, to which Marcos responded by alleging Duterte's previous use of fentanyl as painkiller impaired his judgment; Duterte later dared Marcos to undergo a drug test with him at Luneta Park. Frustrated on the administration's use of taxpayers' money, Duterte initially revived calls advocated by former House Speaker Pantaleon Alvarez for Mindanao to secede from the Philippines; his calls drew disapproval from several lawmakers and former Muslim rebels, prompting Duterte to later retract his calls, saying he only wanted "a better deal for Mindanao". Despite success in holding some rallies, a few suffered setbacks and cancellations after the rally venues were allegedly blocked by the Marcos administration, drawing condemnation from Duterte and his allies.

In 2024, the Council of Europe adopted the Framework Convention on Artificial Intelligence and Human Rights, Democracy and the Rule of Law, the first legally binding international treaty governing artificial intelligence.

== Etymology == The nomenclature for the Do6a venom peptide splits into two components: "Do" refers to the specific Velvet ant species it is extracted from: the Dasymutilla occidentalis. "6a" refers to the specific family and isoform of the Do peptide. Other venom peptides originating from different velvet ant species exist that follow similar nomenclature, such as Dk5a in Dasymutilla klugii.

=== Notes === "Inglorious Bastards" features uncredited vocals from DJ Clue. "M.T.B.T.T.F." stands for "Mike Tyson Blow to the Face". Due to sample clearance issues with "So Be It", a "Pt. II" remix with a different instrumental was uploaded onto streaming platforms in its place upon the album's release. A few hours later, the issue would be resolved, with the original track being reinstated. The initial Kaws and Verdy physical versions of the album did not include either version of "So Be It" or Tyler, the Creator's appearance on "P.O.V.".

Sources: en.wikipedia.org

Background from the literature

The units use strontium-90, and a larger number of such units have been deployed both on the ground and on the ocean floor than have been used on spacecraft, with public regulatory documents suggesting that the US had deployed at least 100–150 during the 1970s and 1980s. In the past, small "plutonium cells" (very small 238Pu-powered RTGs) were used in implanted heart pacemakers to ensure a very long "battery life". As of 2004, about ninety were still in use. By the end of 2007, the number was reported to be down to just nine. The Mound Laboratory Cardiac Pacemaker program began on 1 June 1966, in conjunction with NUMEC. The program was cancelled in 1972, when it was recognized that the heat source would not remain intact during cremation and there was no way to completely ensure that the units would not be cremated with their users' bodies.

=== Metalorganic addition === Interaction of ethylene oxide with organomagnesium compounds, which are Grignard reagents, can be regarded as nucleophilic substitution influenced by carbanion organometallic compounds. The final product of the reaction is a primary alcohol:

Rosalyn Higgins, Baroness Higgins (born 2 June 1937); author of several influential works on international law, including Problems and Process: International Law and How We Use It (1994); former president of International Court of Justice (ICJ); was first female judge elected to the ICJ, and was elected to three-year term as president in 2006; became Queen's Counsel (QC) in 1986, and is bencher of the Inner Temple; served on the UN Human Rights Committee for 14 years; resigned from the Human Rights Committee when she was elected to the International Court of Justice on 12 July 1995, re-elected on 6 February 2000, and ended her second term on 6 February 2009. Her professional appointments include Specialist in International Law, Royal Institute of International Affairs, 1963–1974; Visiting Fellow, London School of Economics, 1974–1978;Professor of International Law, University of Kent at Canterbury, 1978–1981; Professor of International Law, University of London (London School of Economics), 1981–1995; Vice President, British Institute of International and Comparative Law; Member of the UN Human Rights Committee. David Hirsh (born 29 September 1967) author and scholar; professor in Sociology at Goldsmiths, University of London, and co-founder of Engage, a campaign against the academic boycott of Israel. Eric Hobsbawm Marxist historian of Viennese Jewish origin. Anthony Horowitz works include the Alex Rider series Eva Ibbotson (née Wiesner; 21 January 1925 – 20 October 2010) was an Austrian-born British novelist, known for her children's literature.

Necrotizing fasciitis (NF), also known as flesh-eating disease or flesh-eating bacteria, is an infection that kills the body's soft tissue. It is a serious disease that begins and spreads quickly. It is sometimes incorrectly labeled flesh-eating virus. Symptoms include red or purple or black skin, swelling, severe pain, fever, and vomiting. The most commonly affected areas are the limbs and perineum. Bacterial infection is by far the most common cause of necrotizing fasciitis. Despite being called a "flesh-eating disease", bacteria do not eat human tissue. Rather, they release toxins that cause tissue death. Typically, the infection enters the body through a break in the skin, such as a cut or burn. Risk factors include recent trauma or surgery and a weakened immune system due to diabetes or cancer, obesity, alcoholism, intravenous drug use, and peripheral artery disease. It does not usually spread between people. The disease is classified into four types, depending on the infecting organisms. Medical imaging is often helpful to confirm the diagnosis. Necrotizing fasciitis is treated with surgery to remove the infected tissue, and antibiotics. It is considered a surgical emergency. Delays in surgery are associated with a much higher risk of death. Despite high-quality treatment, the risk of death remains 25–35%.

In 1944, Jones became the first Black-American to become a member of the American Society of Refrigeration Engineers. 1953 Merit Award, Phyllis Wheatley Auxiliary (Phillis Wheatley Club of Cleveland, Ohio), "for outstanding achievements which serve as an inspiration to youth." In 1977, he was posthumously inducted into the Minnesota Inventors Hall of Fame. In 1991, the National Medal of Technology was awarded to Joseph A. Numero and Frederick M. Jones. President George Bush presented the awards posthumously to their widows at a ceremony in the White House Rose Garden. Jones was the first Black American to receive the award. In 1996, the Thermo King Model 'C' refrigeration unit, the world's first front-mount refrigeration unit for mobile trucks, was designated an International Mechanical Engineering Landmark by the American Society of Mechanical Engineers. Jones designed and built the prototype from junkyard salvage. The challenges were to build a structural frame and refrigerant tubing connections that would withstand the constant pounding of road vibrations. In 2007, Jones was inducted into the National Inventors Hall of Fame, which honored him as a "Visionary Veteran." In the March 2009 issue of Heavy Duty Truck magazine, editor Tom Berg dubbed Jones "The King of Cool", and wrote that his "technological breakthrough redefined the global marketplace, with cultural reverberations felt from the world's largest cities to its most isolated villages." In 2015, Jones' achievements were recognized by the creators of a Black heritage-themed playground located in Minneapolis.

Sources: en.wikipedia.org

Reference notes

In 1997, Freeman narrated the Academy Award-winning documentary The Long Way Home, about Jewish refugees' liberation after World War II and the establishment of Israel. He also appeared in Steven Spielberg's historical epic Amistad alongside Djimon Hounsou, Anthony Hopkins, and Matthew McConaughey. Based on the events in 1839 aboard the slave ship La Amistad, the film was mostly well-received and earned four nominations at the Academy Awards. The critic from Salon magazine, however, thought the film lacked inspiration and Freeman's role was "utterly cryptic". In that same year, he was cast as psychologist Alex Cross in Kiss the Girls, a thriller based on James Patterson's 1995 novel of the same name. In a mixed review, Peter Stack of San Francisco Chronicle thought Freeman and co-star Ashley Judd gave strong performances despite the lengthy plot. Freeman went on to star in Deep Impact (1998), a science-fiction disaster film in which he played President Tim Beck. The story depicts humanity's attempt to destroy a 7-mile (11 km) wide comet set to collide with Earth and cause a mass extinction. The film was a box-office hit, despite competition from Armageddon, another summer blockbuster of the year. Continuing with the disaster genre, he then starred opposite Christian Slater in 1998's Hard Rain, centering on a heist and man-made treachery amidst a natural disaster in a small Indiana town. The film was unpopular with critics; Lawrence Van Gelder of The New York Times called the characters "one-dimensional" and the film "routine".

== Promotion opportunities == A diener can be promoted to positions in the mortuary and forensic areas of practice. Dieners can advance to positions (such as a forensic morgue technician) and perform tasks of greater complexity and mainly works with a forensic pathologist, over a general pathologist. Dieners can be promoted to supervisory positions based upon the gaining of supervisory and administrative skills.

In mass spectrometry, a matrix is a compound that promotes the formation of ions. Matrix compounds are used in matrix-assisted laser desorption/ionization (MALDI), matrix-assisted ionization (MAI), and fast atom bombardment (FAB).

=== Legal status === Migalastat was authorized for medical use in the European Union in May 2016, and approved for medical use in the United States in August 2018. The FDA granted approval of Galafold to Amicus Therapeutics U.S., Inc. The US Food and Drug Administration (FDA) granted the application for migalastat priority review and orphan drug designations. The European Medicines Agency granted it orphan drug designation in 2006.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

Is AOD-9604 banned in sport?

Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.

Network